| Code Compliance Committee | This committee works to promote compliance among member companies of the JPMA, manages and administers the JPMA’s Code of Practice, and supports member companies’ efforts to promote compliance with the Code. |
| Review Board of Ethical Drug Product Information Brochure | To ensure the proper use of prescription drugs, this committee conducts voluntary reviews of product information summaries for prescription drugs prepared by member companies, as well as promotional materials such as advertisements in professional journals. |
| Pharmaceutical Industrial Policy Committee | To respond swiftly to changes in the environment surrounding the pharmaceutical industry, this committee examines issues and makes policy recommendations regarding industrial promotion, the advancement of innovation, tax systems, and the elimination of tariffs on pharmaceuticals*, among other matters. It also develops countermeasures for issues that cannot be addressed by the standing committees.
|
| Distribution Improvement Committee | To achieve transparency and efficiency in pharmaceutical distribution, we work to resolve various issues through consultations with relevant organizations and government agencies, and make policy recommendations on behalf of JPMA. |
| Drug Evaluation Committee | To promote pharmaceutical research, development, post-marketing safety measures, appropriate use, and medical affairs activities, this committee examines technical and regulatory matters related to these activities and makes policy recommendations and conducts awareness-raising activities. |
| Quality & Technology Committee | This committee conducts surveys and research from an international perspective on pharmaceutical GMP, manufacturing and analytical technologies, and related matters. It also establishes and actively promotes measures to enhance confidence in the quality of pharmaceuticals, thereby contributing to the improvement of medical care and the sound development of the industry. |
| Biopharmaceutical Committee | This committee makes policy recommendations regarding the development of infrastructure to promote the research and development of biopharmaceuticals. It also conducts surveys and research on various technical issues ranging from the research and development of biopharmaceuticals through to production and post-marketing, and makes recommendations for improvements to government agencies and other relevant bodies. |
| Regulatory Affairs Committee | We investigate and examine various issues related to the operational aspects of the Act on Pharmaceutical and Medical Devices, as well as matters concerning pharmaceutical regulations such as drug approval reviews and safety measures. From the perspective of research-based pharmaceutical companies, we make policy proposals regarding various aspects of pharmaceutical administration, such as improving the efficiency of corporate activities and expediting the approval review process. |
| Intellectual Property Committee | To ensure that Japan’s pharmaceutical industry maintains its competitiveness and continues to grow within the global economy, we collaborate with relevant government ministries and other organizations to actively propose policies regarding intellectual property systems not only in Japan but worldwide. We also disseminate information to promote understanding of intellectual property issues in the life sciences field. |
| R & D Committee | We aim to enable member companies to conduct effective drug discovery R&D by gathering and sharing information on key issues related to the research phase, nonclinical trials, and clinical trials; making policy recommendations to the Japan Agency for Medical Research and Development (AMED) and government ministries; and promoting open innovation. |
| International Affairs Committee | From the three perspectives of international expansion, international harmonization, and contributions to global health, we will deepen collaboration with regulatory authorities, pharmaceutical associations in various countries, and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), and carry out activities to resolve international challenges faced by the industry and our member companies. |
| Public Affairs Committee | We carry out activities to raise awareness of pharmaceuticals and the pharmaceutical industry and foster a correct understanding of them. We also actively promote public relations activities to advance the policy proposals advocated by the JPMA. |
| Patient Cooperation Committee | We will actively exchange views with patient organizations to foster mutual understanding, explore initiatives from the patient’s perspective, and strive for better collaboration with patient organizations. We will also work to ensure thorough dissemination of the “Transparency Guideline for Relationships Between Companies and Patient Organizations.” |
| ICH Project | JPMA participates in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and contributes to faster and more efficient drug development through the development of harmonized guidelines. We also organize ICH Public Meetings and Guideline Workshops to share information and raise awareness. |
| APAC Project | The Asia Pharmaceutical Association Consortium (APAC) is a platform comprising 14 research-based pharmaceutical associations in Asia. It identifies challenges and makes policy recommendations to fulfill its mission of “promptly delivering innovative medicines to the people of Asia.”Regarding designated themes, we aim to generate results toward achieving our mission by conducting research and deliberations through relevant working groups and task forces, and by engaging in discussions that include government and academic stakeholders. |
| Consumer Consultation Review Committee | By examining and making recommendations regarding the provision of pharmaceutical information to the public and the role of corporate pharmaceutical consultation services, the group aims to enhance the reliability of the information provided and raise awareness of these services as consultation resources, thereby contributing to “patient-centered healthcare.” |
| Environmental Issue Committee | We examine measures to promote responses to various issues related to global environmental protection, with the aim of advancing environmental protection activities. |
